NCI-2022-07859

OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

This research study is looking at whether a treatment with pembrolizumab is necessary after surgery for patients with early-stage triple-negative breast cancer (TNBC). The trial is designed for patients with early-stage TNBC who achieved pathologic complete response (pCR) after neoadjuvant chemotherapy that also included pembrolizumab. Traditionally, after achieving pCR, patients would receive additional pembrolizumab. This trial is looking to see if skipping this additional pembrolizumab after surgery leads to the same outcome for patients as receiving it.

Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05812807

NCI-2022-07859

Clinical Trial Site: Sinai

To see all available clinical trials click here.